3 results about "Linagliptin" patented technology

The present invention provides an obesity treatment regimen for reducing side effects by low-dose combination administration of linagliptin and liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in obesity treatment compared to administration of each drug alone. Furthermore, the administration dose of liraglutide can be reduced compared to administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc.

The present application relates to the field of medicine, in particular to the use of POU2F2 gene or protein in screening products for preventing or treating atherosclerosis. The present application first discloses that POU2F2 can be used as a key pathogenic target of atherosclerosis, and on this basis, a candidate drug linagliptin is screened. The experimental results show that in the in vitro atherosclerosis model, linagliptin can significantly inhibit the expression of POU2F2 and down-regulate the levels of inflammatory factors and adhesion molecules. The findings clarify the mechanism of linagliptin in regulating POU2F2 related signal pathways, inhibiting vascular inflammatory response and reducing vascular endothelial damage, and fully show that it has a good clinical application prospect in preparing drugs for preventing or treating atherosclerosis and its related cardiovascular and cerebrovascular diseases.

The present invention provides an injectable depot composition comprising linagliptin and low-dose liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the administration of each drug alone. In addition, the administration dose of liraglutide can be reduced compared to the administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc. In addition, compared to the conventional liraglutide dosage form of once-daily subcutaneous injection, the depot composition of linagliptin and liraglutide of the present invention can significantly improve patient convenience and patient compliance by unifying the administration route and improving the administration cycle.